Recently, the anti-IL-36 receptor antibody spesolimab gained approval in the United States,14 Europe,15 Japan,16 and China17 for the treatment of GPP flares, based on a placebo-controlled, randomized Phase II trial (NCT03782792). This evidence concerns the gene IL1RL2 and psoriasis 14, pustular.